Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mark Richards

Showing results (61-70 of 390) with videos related to

Pageof 39
Sort By:
JACC. Heart Failure|November 3, 2023
Combined Inhibition of Phosphodiesterase-5 and -9 in Experimental Heart FailureMiriam T Rademaker, Nicola J A Scott, Christopher J Charles, et al.
Frontiers in Bioengineering and Biotechnology|October 31, 2022
Material property alterations for phenotypes of heart failure with preserved ejection fraction: A numerical study of subject-specific porcine modelsJonathan Weissmann, Christopher J Charles, A Mark Richards, et al.
BMC Medical Research Methodology|February 25, 2025
Accounting for extent of non-compliance when estimating treatment effects on an ordinal outcome in randomized clinical trialsJunxian Zhu, Jialiang Li, A Mark Richards, et al.
The American Journal of Cardiology|March 28, 2006
Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart diseaseCara A Wasywich, Mark W I Webster, A Mark Richards, et al.
Clinical Biochemistry|February 8, 2020
Analytical and biological assessment of circulating human erythroferroneSarah Appleby, Janice Chew-Harris, Richard W Troughton, et al.
European Journal of Heart Failure|August 9, 2002
Plasma brain natriuretic peptide after long-term treatment for heart failure in general practiceGraham McGeoch, John Lainchbury, G Ian Town, et al.
Clinical Biochemistry|May 27, 2019
Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individualsJanice Chew-Harris, Sarah Appleby, A Mark Richards, et al.
Lancet (London, England)|September 21, 2002
Plasma urotensin II in heart failureA Mark Richards, M Gary Nicholls, John G Lainchbury, et al.
The Journal of Applied Laboratory Medicine|September 28, 2025
Influence of Protein Glycosylation on the Measurement of Soluble Urokinase Plasminogen Activator ReceptorJaya Montecillo, Richard W Troughton, A Mark Richards, et al.
Annals of Medicine|June 15, 2007
The effects of medications on circulating levels of cardiac natriuretic peptidesRichard W Troughton, A Mark Richards, Tim G Yandle, et al.
Pageof 39

Showing results (61-70 of 390) with videos related to

Sort By:
Pageof 39
JACC. Heart Failure|November 3, 2023
Combined Inhibition of Phosphodiesterase-5 and -9 in Experimental Heart FailureMiriam T Rademaker, Nicola J A Scott, Christopher J Charles, et al.
Frontiers in Bioengineering and Biotechnology|October 31, 2022
Material property alterations for phenotypes of heart failure with preserved ejection fraction: A numerical study of subject-specific porcine modelsJonathan Weissmann, Christopher J Charles, A Mark Richards, et al.
BMC Medical Research Methodology|February 25, 2025
Accounting for extent of non-compliance when estimating treatment effects on an ordinal outcome in randomized clinical trialsJunxian Zhu, Jialiang Li, A Mark Richards, et al.
The American Journal of Cardiology|March 28, 2006
Coronary sinus and ascending aortic levels of aldosterone, angiotensin II, and B-type natriuretic peptide in patients with aortic stenosis and in patients with coronary heart diseaseCara A Wasywich, Mark W I Webster, A Mark Richards, et al.
Clinical Biochemistry|February 8, 2020
Analytical and biological assessment of circulating human erythroferroneSarah Appleby, Janice Chew-Harris, Richard W Troughton, et al.
European Journal of Heart Failure|August 9, 2002
Plasma brain natriuretic peptide after long-term treatment for heart failure in general practiceGraham McGeoch, John Lainchbury, G Ian Town, et al.
Clinical Biochemistry|May 27, 2019
Analytical, biochemical and clearance considerations of soluble urokinase plasminogen activator receptor (suPAR) in healthy individualsJanice Chew-Harris, Sarah Appleby, A Mark Richards, et al.
Lancet (London, England)|September 21, 2002
Plasma urotensin II in heart failureA Mark Richards, M Gary Nicholls, John G Lainchbury, et al.
The Journal of Applied Laboratory Medicine|September 28, 2025
Influence of Protein Glycosylation on the Measurement of Soluble Urokinase Plasminogen Activator ReceptorJaya Montecillo, Richard W Troughton, A Mark Richards, et al.
Annals of Medicine|June 15, 2007
The effects of medications on circulating levels of cardiac natriuretic peptidesRichard W Troughton, A Mark Richards, Tim G Yandle, et al.
Pageof 39